News

The Company also announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with Systemic Lupus Erythematosus (SLE). "We are advancing XmAb5871 in IgG4-RD

The agreement covers the compound BI655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis. BI 655066 selectively blocks IL-23, a key protein involved in skin

Rintega (rindopepimut) is an investigational immunotherapy that targets the tumor specific oncogene EGFRvIII, a functional and permanently activated mutation of the epidermal growth factor receptor (EGFR) which has

Two doses of the drug were tested against a placebo and an oral antiviral called ribavarin to evaluate their effect on survival of immune-deficient mice infected with Zika

The companies have signed an agreement in which Bristol-Myers Squibb has become a LabCentral platinum sponsor. As part of the agreement, Bristol-Myers Squibb can nominate up to two

The approval is based on data from the Phase 3 RESONATE-2 (PCYC-1115) study, the first head-to-head clinical trial comparing IMBRUVICA to a chemotherapy agent. Results showed IMBRUVICA significantly

Detailed results of this combined analysis of UNCOVER-2 and UNCOVER-3 were presented during the American Academy of Dermatology (AAD) Annual Meeting taking place March 4-8 in Washington, D.C.

All patients who completed 12 weeks of low-dose maintenance therapy were desensitized to levels of peanut protein beyond the 250-300 mg typically found in one peanut kernel. Low-Dose

Remedy Pharmaceuticals CEO Sven Jacobson said: "Our End-of-Phase 2 meeting was a decisive milestone for the Company as we advance the clinical development of CIRARA.. "We are pleased